Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats.

Recombinant adeno-associated virus serotype 9 (rAAV2/9) and pseudotype rhesus-10 (rAAV2/rh10) are used for gene delivery, especially into the central nervous system. Both serotypes cross the blood-brain barrier and mediate stable long-term transduction in dividing and nondividing cells. Among possible routes of administration, intracardiac injection holds the potential for widespread vector diffusion associated with a relatively simple approach. In this study adopting the intracardiac route, we compare the cell-specific tropism and transfection efficacy of a panel of engineered rAAV2/9 and rAAV2/rh10 vectors encoding the enhanced green fluorescent protein. We observed transduction in the brain and peripherally, with a predominant neuronal tropism while the various serotypes achieved different expression patterns.

[1]  E. Bézard,et al.  In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson’s disease , 2017, Gene Therapy.

[2]  Tianyun Wang,et al.  RETRACTED ARTICLE: Impact of different promoters, promoter mutation, and an enhancer on recombinant protein expression in CHO cells , 2017, Scientific Reports.

[3]  R. Chandler,et al.  Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models. , 2017, Human gene therapy.

[4]  Y. Saga,et al.  Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract , 2017, Gene Therapy.

[5]  E. Bézard,et al.  Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity , 2017, Acta neuropathologica communications.

[6]  Samantha Parker,et al.  Adeno-Associated Virus-Based Gene Therapy for CNS Diseases , 2016, Human gene therapy.

[7]  J. Prieto,et al.  Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Axel Rossi,et al.  Intégration des vecteurs AAV et mutagenèse insertionnelle , 2016 .

[9]  K. Masamoto,et al.  Establishment and evaluation of a new highly metastatic tumor cell line 5a-D-Luc-ZsGreen expressing both luciferase and green fluorescent protein. , 2016, International journal of oncology.

[10]  Qin Li,et al.  Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression , 2015, Acta neuropathologica communications.

[11]  Chang Hoon Shin,et al.  Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1 , 2015, Oncotarget.

[12]  E. Bézard,et al.  Systemic gene delivery to the central nervous system using Adeno-associated virus , 2014, Front. Mol. Neurosci..

[13]  S. Salvador,et al.  Immunohistochemical, tomographic, and histological study on onlay bone graft remodeling. Part III: allografts. , 2013, Clinical oral implants research.

[14]  M. Levivier,et al.  A next step in adeno‐associated virus‐mediated gene therapy for neurological diseases: regulation and targeting , 2013, British journal of clinical pharmacology.

[15]  R. Muschel,et al.  Ultrasonography-guided intracardiac injection: an improvement for quantitative brain colonization assays. , 2013, The American journal of pathology.

[16]  E. Bézard,et al.  Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss , 2013, Annals of neurology.

[17]  D. Borchelt,et al.  Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain , 2013, PloS one.

[18]  S. Muramatsu,et al.  Systemic Delivery of Tyrosine-Mutant AAV Vectors Results in Robust Transduction of Neurons in Adult Mice , 2013, BioMed research international.

[19]  R. Samulski,et al.  Viral vectors for gene delivery to the central nervous system , 2012, Neurobiology of Disease.

[20]  W. Low,et al.  Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. , 2012, Molecular genetics and metabolism.

[21]  Qin Li,et al.  Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques , 2012, Scientific Reports.

[22]  A. Baiker,et al.  Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. , 2012, Human gene therapy methods.

[23]  Ruhang Tang,et al.  Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. , 2012, Human gene therapy methods.

[24]  J. Flannery,et al.  Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9 , 2011, Gene Therapy.

[25]  J. Grieger,et al.  Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs , 2011, Gene Therapy.

[26]  E. Bézard,et al.  Endogenous morphine-like compound immunoreactivity increases in parkinsonism. , 2011, Brain : a journal of neurology.

[27]  W. Hauswirth,et al.  Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  S. Zolotukhin,et al.  High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  G. Jayandharan,et al.  High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. , 2010, Human gene therapy.

[30]  D. Duan,et al.  Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. , 2010, Human gene therapy.

[31]  L. Zhong,et al.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. , 2010, Human gene therapy.

[32]  P. Pivirotto,et al.  Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  M. Rich,et al.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2010, Nature Biotechnology.

[34]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Andrew King,et al.  Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium , 2009, Acta Neuropathologica.

[36]  J. Wilson,et al.  Tailoring the AAV vector capsid for gene therapy , 2009, Gene Therapy.

[37]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[38]  H. Sweeney,et al.  Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. , 2008, Human gene therapy.

[39]  N. Muzyczka,et al.  Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses , 2008, Proceedings of the National Academy of Sciences.

[40]  R. H. Smith.  Adeno-associated virus integration: virus versus vector , 2008, Gene Therapy.

[41]  D. Jenkins,et al.  Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice , 2005, Breast Cancer Research.

[42]  F. Gage,et al.  Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model , 2003, Science.

[43]  L. V. von Segesser,et al.  Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. , 2003, International journal of cardiology.

[44]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[45]  M. King,et al.  Dose and Promoter Effects of Adeno-Associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain , 2002, Experimental Neurology.

[46]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.